[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100055063":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":7,"locations":16,"responsibleParty":7,"collaborators":7,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":34,"acronym":7,"eligibilityCriteria":35,"healthyVolunteers":32,"sex":36,"minAge":37,"maxAge":7,"enrollmentInfo":38,"targetDuration":7,"studyType":40,"phases":41,"briefSummary":43,"conditions":44,"keywords":46,"overallStatus":52,"whyStopped":7,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":57,"locationsCount":59},{"fullName":5,"class":6},"NIH AIDS Clinical Trials Information Service","INDUSTRY",null,[9,12,14],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Indinavir sulfate",{"type":10,"name":13,"description":7,"armGroupLabels":7,"otherNames":7},"Lamivudine",{"type":10,"name":15,"description":7,"armGroupLabels":7,"otherNames":7},"Zidovudine",[17],{"facility":18,"status":7,"city":19,"state":20,"zip":21,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":7},"Merck & Co Inc","Whitehouse Station","New Jersey","088890100","United States","US",{"type":25,"coordinates":26},"Point",[27,28],-74.77044,40.61538,{"lat":28,"lon":27},"100055063","a-six-month-safety-and-antiviral-study-in-hiv-1-seropositive-azt-experienced-patients-with-cd4-counts-less-than-or-equal-to-50-cellsmm3-to-evaluate-mk-639-alone-versus-zidovudine-azt-and-3tc-versus-the-combination-of-mk-639-with-azt3tc-100055063",false,"NCT00002155","A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells\u002Fmm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT\u002F3TC","Inclusion Criteria\n\nConcurrent Medication:\n\nAllowed for all patients:\n\n* Standard prophylaxis for opportunistic infections.\n* Continuation of treatment for opportunistic infection.\n\nAllowed for open-label study patients:\n\n* Rifampin.\n\nPatients must have:\n\n* HIV positivity.\n* CD4 count \\\u003C= 50 cells\u002Fmm3.\n* More than 6 months of prior AZT (blinded study only).\n\nNOTE:\n\n* Patients on the open-label study must have AZT intolerance or have \\\u003C 6 months of prior AZT.\n\nPrior Medication:\n\nRequired for blinded study patients:\n\n* \\> 6 months of prior AZT.\n\nRequired for open-label study patients:\n\n* \\\u003C 6 months of prior AZT.\n\nAllowed for open-label study patients:\n\n* Prior 3TC.\n\nExclusion Criteria\n\nConcurrent Medication:\n\nExcluded in all patients:\n\n* Immunosuppressants.\n\nExcluded in blinded study patients:\n\n* AZT, ddI, ddC, or d4T.\n* Rifampin.\n\nExcluded in open-label study patients:\n\n* 3TC.\n\nPrior Medication:\n\nExcluded in all patients:\n\n* Prior protease inhibitors.\n* Investigational agents and immunomodulators within 30 days prior to study entry.\n* Immunosuppressants within 2 weeks prior to study entry.\n\nExcluded in blinded study patients:\n\n* Any prior 3TC.\n* AZT, ddI, ddC, or d4T within 2 weeks prior to study entry.\n\nExcluded in open-label study patients:\n\n3TC within 30 days prior to study entry.","ALL","18 Years",{"count":39,"type":7},600,"INTERVENTIONAL",[42],"NA","To compare effects on CD4 counts and serum viral RNA among HIV-seropositive, zidovudine (AZT)-experienced patients in three treatment arms: indinavir sulfate ( MK-639; Crixivan ) plus AZT plus lamivudine ( 3TC ) versus MK-639 alone versus AZT\u002F3TC.",[45],"HIV Infections",[47,48,49,15,50,13,51],"Drug Therapy, Combination","Acquired Immunodeficiency Syndrome","Antiviral Agents","HIV Protease Inhibitors","Indinavir","COMPLETED","2005-06-23",{"date":55,"type":56},"2005-06-24","ESTIMATED",{"name":58,"class":6},"Merck Sharp & Dohme LLC",1]